{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:49Z","timestamp":1787841529814,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12282-026-01881-0","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:18:04Z","timestamp":1781288284000},"page":"947-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Annual report of national clinical database-breast cancer registry in 2023: systemic therapy for small breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1623-869X","authenticated-orcid":false,"given":"Shinsuke","family":"Sasada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Kumamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kinukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Tanakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nagahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"1881_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s12282-020-01081-4","volume":"27","author":"M Kubo","year":"2020","unstructured":"Kubo M, Kumamaru H, Isozumi U, Miyashita M, Nagahashi M, Kadoya T, et al. Annual report of the Japanese Breast Cancer Society registry for 2016. Breast Cancer. 2020;27:511\u20138. https:\/\/doi.org\/10.1007\/s12282-020-01081-4.","journal-title":"Breast Cancer"},{"key":"1881_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12282-025-01671-0","volume":"32","author":"M Nagahashi","year":"2022","unstructured":"Nagahashi M, Kumamaru H, Kinukawa N, Iwamoto T, Kawashima M, Kinoshita T, et al. Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression. Breast Cancer. 2022;32:217\u201326. https:\/\/doi.org\/10.1007\/s12282-025-01671-0.","journal-title":"Breast Cancer"},{"key":"1881_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-025-01698-3","author":"T Konishi","year":"2021","unstructured":"Konishi T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Iwamoto T, et al. Annual report of national clinical database-breast cancer registry in 2021: characteristics categorized by body mass index and menopause status. Breast Cancer. 2021. https:\/\/doi.org\/10.1007\/s12282-025-01698-3.","journal-title":"Breast Cancer."},{"key":"1881_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12282-023-01532-8","volume":"31","author":"Y Sagara","year":"2024","unstructured":"Sagara Y, Kumamaru H, Niikura N, Miyashita M, Konishi T, Iwamoto T, et al. 2020 Annual report of national clinical database-breast cancer registry: 10-year mortality of elderly breast cancer patients in Japan. Breast Cancer. 2024;31:179\u201384. https:\/\/doi.org\/10.1007\/s12282-023-01532-8.","journal-title":"Breast Cancer"},{"key":"1881_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12282-023-01526-6","volume":"31","author":"M Miyashita","year":"2024","unstructured":"Miyashita M, Kumamaru H, Niikura N, Sagara Y, Konishi T, Iwamoto T, et al. Annual report of the Japanese Breast Cancer Registry for 2019. Breast Cancer. 2024;31:16\u201323. https:\/\/doi.org\/10.1007\/s12282-023-01526-6.","journal-title":"Breast Cancer"},{"key":"1881_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12282-022-01423-4","volume":"30","author":"K Tada","year":"2023","unstructured":"Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, et al. Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018. Breast Cancer. 2023;30:157\u201366. https:\/\/doi.org\/10.1007\/s12282-022-01423-4.","journal-title":"Breast Cancer"},{"key":"1881_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s12282-020-01139-3","volume":"27","author":"N Hayashi","year":"2020","unstructured":"Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K, et al. Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer. 2020;27:803\u20139. https:\/\/doi.org\/10.1007\/s12282-020-01139-3.","journal-title":"Breast Cancer"},{"key":"1881_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12282-015-0599-6","volume":"22","author":"J Kurebayashi","year":"2015","unstructured":"Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22:235\u201344. https:\/\/doi.org\/10.1007\/s12282-015-0599-6.","journal-title":"Breast Cancer"},{"key":"1881_CR9","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/cam4.678","volume":"5","author":"M Kawai","year":"2016","unstructured":"Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Cancer Med. 2016;5:1328\u201340. https:\/\/doi.org\/10.1002\/cam4.678.","journal-title":"Cancer Med"},{"key":"1881_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/annonc\/mdv611","volume":"27","author":"N Niikura","year":"2016","unstructured":"Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27:480\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdv611.","journal-title":"Ann Oncol"},{"key":"1881_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10549-016-3984-8","volume":"160","author":"A Kataoka","year":"2016","unstructured":"Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, et al. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;160:163\u201372. https:\/\/doi.org\/10.1007\/s10549-016-3984-8.","journal-title":"Breast Cancer Res Treat"},{"key":"1881_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12282-019-00997-w","volume":"27","author":"T Hojo","year":"2004","unstructured":"Hojo T, Masuda N, Iwamoto T, Niikura N, Anan K, Aogi K, et al. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004\u20132009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. Breast Cancer. 2004;27:85\u201391. https:\/\/doi.org\/10.1007\/s12282-019-00997-w.","journal-title":"Breast Cancer"},{"key":"1881_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10549-019-05413-7","volume":"178","author":"M Kubo","year":"2019","unstructured":"Kubo M, Kawai M, Kumamaru H, Miyata H, Tamura K, Yoshida M, et al. A population-based recurrence risk management study of patients with pT1 node-negative HER2\u2009+\u2009breast cancer: a National Clinical Database study. Breast Cancer Res Treat. 2019;178:647\u201356. https:\/\/doi.org\/10.1007\/s10549-019-05413-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1881_CR14","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1245\/s10434-019-07453-1","volume":"26","author":"M Miyashita","year":"2019","unstructured":"Miyashita M, Niikura N, Kumamaru H, Miyata H, Iwamoto T, Kawai M, et al. Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients: a study from the Japanese Breast Cancer Registry. Ann Surg Oncol. 2019;26:2475\u201385. https:\/\/doi.org\/10.1245\/s10434-019-07453-1.","journal-title":"Ann Surg Oncol"},{"key":"1881_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12282-021-01307-z","volume":"29","author":"D Yotsumoto","year":"2022","unstructured":"Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, et al. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Breast Cancer. 2022;29:1\u20138. https:\/\/doi.org\/10.1007\/s12282-021-01307-z.","journal-title":"Breast Cancer"},{"key":"1881_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2022.05.017","volume":"172","author":"A Yamada","year":"2022","unstructured":"Yamada A, Hayashi N, Kumamaru H, Nagahashi M, Usune S, Asaga S, et al. Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1\u20133 lymph node metastases: a retrospective cohort study based on the Japanese Breast Cancer Registry. Eur J Cancer. 2022;172:31\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.017.","journal-title":"Eur J Cancer"},{"key":"1881_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10549-020-05869-y","volume":"184","author":"R Ogiya","year":"2020","unstructured":"Ogiya R, Niikura N, Kumamaru H, Takeuchi Y, Okamura T, Kinoshita T, et al. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. Breast Cancer Res Treat. 2020;184:585\u201396. https:\/\/doi.org\/10.1007\/s10549-020-05869-y.","journal-title":"Breast Cancer Res Treat"},{"key":"1881_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12282-022-01348-y","volume":"29","author":"M Terada","year":"2022","unstructured":"Terada M, Miyashita M, Kumamaru H, Miyata H, Tamura K, Yoshida M, et al. Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Breast Cancer. 2022;29:698\u2013708. https:\/\/doi.org\/10.1007\/s12282-022-01348-y.","journal-title":"Breast Cancer"},{"key":"1881_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10549-022-06749-3","volume":"196","author":"T Aihara","year":"2022","unstructured":"Aihara T, Kumamaru H, Ishitobi M, Miyashita M, Miyata H, Tamura K, et al. Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. Breast Cancer Res Treat. 2022;196:635\u201345. https:\/\/doi.org\/10.1007\/s10549-022-06749-3.","journal-title":"Breast Cancer Res Treat"},{"key":"1881_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s12282-022-01378-6","volume":"29","author":"A Shimomura","year":"2022","unstructured":"Shimomura A, Nagahashi M, Kumamaru H, Aogi K, Asaga S, Hayashi N, et al. Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. Breast Cancer. 2022;29:985\u201392. https:\/\/doi.org\/10.1007\/s12282-022-01378-6.","journal-title":"Breast Cancer"},{"key":"1881_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-023-07022-x","volume":"201","author":"Y Adachi","year":"2023","unstructured":"Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, et al. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Res Treat. 2023;201:397\u2013408. https:\/\/doi.org\/10.1007\/s10549-023-07022-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1881_CR22","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.breast.2025.104567","volume":"83","author":"M Ogita","year":"2025","unstructured":"Ogita M, Kumamaru H, Kubo M, Kinukawa N, Niikura N, Saji S, et al. Survival of patients with squamous cell carcinoma of the breast compared with invasive ductal carcinoma by biological subtype: a matched analysis of the Japanese national clinical database-breast cancer registry. Breast. 2025;83:104567. https:\/\/doi.org\/10.1016\/j.breast.2025.104567.","journal-title":"Breast"},{"key":"1881_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12282-024-01604-3","volume":"31","author":"S Sasada","year":"2024","unstructured":"Sasada S, Kumamaru H, Hayashi N, Kinukawa N, Toi M, Jinno H, et al. Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese Nationwide Registry. Breast Cancer. 2024;31:909\u201316. https:\/\/doi.org\/10.1007\/s12282-024-01604-3.","journal-title":"Breast Cancer"},{"key":"1881_CR24","doi-asserted-by":"publisher","first-page":"104460","DOI":"10.1016\/j.breast.2025.104460","volume":"81","author":"T Taji","year":"2025","unstructured":"Taji T, Kumamaru H, Kataoka Y, Iijima K, Suwa H, Ishiguro H, et al. Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry. Breast. 2025;81:104460. https:\/\/doi.org\/10.1016\/j.breast.2025.104460.","journal-title":"Breast"},{"key":"1881_CR25","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. (Version 5. 2025). National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed January 4, 2026."},{"key":"1881_CR26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","volume":"30","author":"M Terada","year":"2023","unstructured":"Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer. 2023;30:872\u201384. https:\/\/doi.org\/10.1007\/s12282-023-01505-x.","journal-title":"Breast Cancer"},{"key":"1881_CR27","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023.","journal-title":"Ann Oncol"},{"key":"1881_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10549-023-07097-6","volume":"202","author":"S Sasada","year":"2023","unstructured":"Sasada S, Kondo N, Hashimoto H, Takahashi Y, Terata K, Kida K, et al. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a\/bN0M0 breast cancer. Breast Cancer Res Treat. 2023;202:473\u201383. https:\/\/doi.org\/10.1007\/s10549-023-07097-6.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01881-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:58:31Z","timestamp":1787839111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01881-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1881"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01881-0","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Grants or contracts from any entity\u2014S Sasada: Chugai, Daiichi-Sankyo, Eli Lilly, Gilead Sciences, and Nipro; HK: Amgen, National Clinical Database, and Pfizer. MK: Advalife Science, Chugai\/Roche, Eli Lilly, Fujiwara Memorial Foundation, JBCRG, and Merck; S Saji: AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead Sciences, MSD, Sanofi, Taiho, and Takeda; NN: Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Eisai, and Novartis; NT: Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa Kirin, and Taiho. Consulting fees\u2014HK: EPS corporation; MY: Roche. Payment or honoraria for lectures\u2014S Sasada: Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa Kirin; HK: Novartis; MK: AstraZeneca, Chugai, Daiichi-Sankyo, Devicor Medical, Eisai, Guardant Health AMEA, and Pfizer; S Saji: AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead Sciences, Kyowa Kirin, MSD, Nippon Kayaku, Novartis, Ono, Pfizer, Taiho, and Takeda; MN: AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Exact Sciences, Kyowa Kirin, MSD, Pfizer, and Taiho; MM: AstraZeneca, Chugai, Daiichi-Sankyo, Eli Lilly, Exact Sciences, Gilead Sciences, MSD, and Pfizer; MY: Agilent Technologies, Chugai, Daiichi-Sankyo, MSD, Ono, and Roche. YS: AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lily, Kyowa Kirin, MSD, Nippon Kayaku, Pfizer, and Sysmex; NN: AstraZeneca, Chugai, Daiichi-Sankyo, Eli Lilly, MSD, and Pfizer; NT: AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa Kirin, MSD, Pfizer, and Takeda. Participation on a Data Safety Monitoring Board or Advisory Board\u2014T Konishi: Health Insurance Claims Review and Reimbursement Services. S Saji: AstraZeneca, Chugai\/Roche, Daiichi-Sankyo, Eli Lilly, Kyowa Kirin, MSD, and Pfizer; MY: Daiichi-Sankyo. Leadership or fiduciary role\u2014S Saji: JBCRG, and JBCS. Stock or stock options\u2014 S Sasada: Daiichi-Sankyo.Other financial or non-financial interests\u2014HK: affiliation to the social collaboration department at the University of Tokyo supported by the National Clinical Database, Intuitive Surgical Sarl, Johnson and Johnson, and Nipro; NK: employed as a specially appointed academic staff member with funding provided by National Clinical Database. NT: director of the Japanese Breast Cancer Society, and chairperson of the Registration Database Committee of the Japanese Breast Cancer Society.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any animal studies conducted by any of the authors. All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Formal consent was not required for this study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}